SCHEMBL3243563

SCHEMBL3243563

CC1(C)CCc2cc(Cl)c(O)cc2O1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FTO Q9C0B1 1/20 0.43
CTSB P07858 1/20 0.42
KMT2A Q03164 2/20 0.39
BCHE P06276 1/20 0.38
MAPT P10636 2/20 0.37
NPC1 O15118 2/20 0.36
RAB9A P51151 2/20 0.36
PKM P14618 2/20 0.36
PKLR P30613 1/20 0.36
COXFA4 O00483 1/20 0.36
MGAM O43451 2/20 0.36
GAA P10253 2/20 0.36
SI P14410 2/20 0.36
MGAM2 Q2M2H8 2/20 0.36
AKT1 P31749 1/20 0.35
SCN9A Q15858 1/20 0.35
DRD2 P14416 1/20 0.35
DRD4 P21917 1/20 0.35
DRD3 P35462 1/20 0.35
MEN1 O00255 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23423286 0.81 PKM (0.41) KMT2AMAPTNPC1RAB9APKM
SCHEMBL31253957 0.80 CTSB (0.42) CTSBKMT2ABCHEMAPTNPC1
SCHEMBL2484407 0.78 BCHE (0.45) CTSBKMT2ABCHEMAPTNPC1
SCHEMBL5308527 0.78 NPC1 (0.43) CTSBKMT2AMAPTNPC1RAB9A
SCHEMBL30455669 0.77 PKM (0.43) KMT2AMAPTNPC1RAB9APKM
SCHEMBL4971813 0.76 CTSB (0.42) CTSBKMT2ABCHEMAPTNPC1
SCHEMBL3184205 0.76 AKT1 (0.56) CTSBMAPTNPC1RAB9APKM
SCHEMBL30513267 0.76 AKT1 (0.56) CTSBMAPTNPC1RAB9APKM
SCHEMBL10820252 0.74 CTSB (0.43) CTSBKMT2ABCHEMAPTNPC1
SCHEMBL29401664 0.74 BCHE (0.65) BCHECOXFA4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1539137-B1 PPAR ALPHA SELECTIVE COMPOUNDS FOR THE TREATMENT OF DYSLIPIDEMIA AND OTHER LIPID DISORDERS MERCK SHARP & DOHME (US) 2010-05-26 EP disclosed
EP-1539137-B1 PPAR ALPHA SELECTIVE COMPOUNDS FOR THE TREATMENT OF DYSLIPIDEMIA AND OTHER LIPID DISORDERS MERCK SHARP & DOHME (US) 2010-05-26 EP disclosed
US-7297715-B2 PPAR alpha selective compounds for the treatment of dyslipidemia and other lipid disorders MERCK & CO., INC. (US) 2007-11-20 US disclosed
US-7297715-B2 PPAR alpha selective compounds for the treatment of dyslipidemia and other lipid disorders MERCK & CO., INC. (US) 2007-11-20 US disclosed
US-7297715-B2 PPAR alpha selective compounds for the treatment of dyslipidemia and other lipid disorders MERCK & CO., INC. (US) 2007-11-20 US disclosed
EP-1539137-A4 PPAR ALPHA SELECTIVE COMPOUNDS FOR THE TREATMENT OF DYSLIPIDEMIA AND OTHER LIPID DISORDERS MERCK & CO INC (US) 2007-11-14 EP disclosed
US-20060089404-A1 Ppar alpha selective compounds for the treatment of dyslipidemia and other lipid disorders MERCK SHARP & DOHME CORP. 2006-04-27 US disclosed
EP-1539137-A1 PPAR ALPHA SELECTIVE COMPOUNDS FOR THE TREATMENT OF DYSLIPIDEMIA AND OTHER LIPID DISORDERS Merck & Co., Inc. (US) 2005-06-15 EP disclosed
WO-2004010992-A1 PPAR ALPHA SELECTIVE COMPOUNDS FOR THE TREATMENT OF DYSLIPIDEMIA AND OTHER LIPID DISORDERS MERCK & CO., INC. (US) 2004-02-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060089404-A1 Ppar alpha selective compounds for the treatment of dyslipidemia and other lipid disorders PPARA, PPARG, PPARD FTO 4751/4885CTSB 2263/4885KMT2A 2083/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.